Guidant Strengthens Resolve To Build Vulnerable Plaque Market
This article was originally published in The Gray Sheet
Executive Summary
Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy
You may also be interested in...
Guidant, Boston Scientific Stocks Weather DES Issues
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May
Guidant, Boston Scientific Stocks Weather DES Issues
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May
Iridex/Miravant PDT For Macular Degeneration Granted FDA Expedited Review
Miravant Medical Technologies and Iridex Corp. are seeking a broader indication for their photodynamic therapy laser than current offerings to treat age-related macular degeneration (AMD)